Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EZH2 | Q15910 | 2/20 | 0.59 |
| ▸ | RAB9A | P51151 | 5/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.57 |
| ▸ | MAPT | P10636 | 4/20 | 0.57 |
| ▸ | MEN1 | O00255 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | HPGD | P15428 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 4/20 | 0.50 |
| ▸ | CASP3 | P42574 | 2/20 | 0.50 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.50 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.50 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.46 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.44 |
| ▸ | TUBB | P07437 | 1/20 | 0.44 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.44 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4364501 | 0.85 | EZH2 (0.49) | EZH2RAB9AKDM4EMAPTMEN1 | |
| SCHEMBL14873891 | 0.78 | RIPK1 (0.55) | — | |
| SCHEMBL5559572 | 0.76 | KDM4E (0.61) | EZH2RAB9AKDM4EMAPTMEN1 | |
| SCHEMBL7824283 | 0.76 | EZH2 (0.50) | EZH2RAB9AKDM4EMAPTMEN1 | |
| SCHEMBL7824287 | 0.76 | EZH2 (0.50) | EZH2RAB9AKDM4EMAPTMEN1 | |
| SCHEMBL229717 | 0.75 | PDGFRB (0.46) | MAPTCYP2A6TUBB4ATUBBTUBA3C | |
| SCHEMBL3878366 | 0.74 | ALDH1A1 (0.40) | EZH2KDM4EMAPTALDH1A1HPGD | |
| SCHEMBL7837215 | 0.73 | EZH2 (0.47) | EZH2RAB9AKDM4EMAPTMEN1 | |
| SCHEMBL7824833 | 0.73 | EZH2 (0.52) | EZH2RAB9AKDM4EMAPTMEN1 | |
| SCHEMBL7837218 | 0.73 | EZH2 (0.47) | EZH2RAB9AKDM4EMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-11225655-B2 | Bi-functional complexes and methods for making and using such complexes | NUEVOLUTION A/S (DK) | 2022-01-18 | — | — | US | disclosed |
| EP-3540059-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2019-09-18 | — | — | EP | disclosed |
| EP-2558577-B1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION AS (DK) | 2018-12-12 | — | — | EP | disclosed |
| US-20130281324-A1 | BI-FUNCTINAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2013-10-24 | — | — | US | disclosed |
| US-8420638-B2 | Triheterocyclic compounds and compositions thereof | GEMIN X PHARMACEUTICALS CANADA INC. (CA) | 2013-04-16 | — | — | US | disclosed |
| US-8420638-B2 | Triheterocyclic compounds and compositions thereof | GEMIN X PHARMACEUTICALS CANADA INC. (CA) | 2013-04-16 | — | — | US | disclosed |
| US-8420638-B2 | Triheterocyclic compounds and compositions thereof | GEMIN X PHARMACEUTICALS CANADA INC. (CA) | 2013-04-16 | — | — | US | disclosed |
| EP-1644363-B1 | TRIHETEROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING CANCER | GEMIN X PHARMACEUTICALS CANADA INC (CA) | 2012-02-22 | — | — | EP | disclosed |
| EP-1644363-B1 | TRIHETEROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING CANCER | GEMIN X PHARMACEUTICALS CANADA INC (CA) | 2012-02-22 | — | — | EP | disclosed |
| US-20080076739-A1 | Methods for treating arthritis using triheterocyclic compounds | GEMIN X BIOTECHNOLOGIES INC. (CA) | 2008-03-27 | — | — | US | disclosed |
| US-20080076739-A1 | Methods for treating arthritis using triheterocyclic compounds | GEMIN X BIOTECHNOLOGIES INC. (CA) | 2008-03-27 | — | — | US | disclosed |
| EP-1853255-A1 | METHODS FOR TREATING ARTHRITIS USING TRIHETEROCYCLIC COMPOUNDS | Gemin X Biotechnologies Inc. (CA) | 2007-11-14 | — | — | EP | disclosed |
| WO-2006089397-A1 | METHODS FOR TREATING ARTHRITIS USING TRIHETEROCYCLIC COMPOUNDS | GEMIN X BIOTECHNOLOGIES INC. (CA) | 2006-08-31 | — | — | WO | disclosed |
| EP-1644363-A1 | TRIHETEROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING CANCER OR VIRAL DISEASES | Gemin X Biotechnologies Inc. (CA) | 2006-04-12 | — | — | EP | disclosed |
| US-20060035945-A1 | Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases | INVESTISSEMENT QUEBEC (CA) | 2006-02-16 | — | — | US | disclosed |
| WO-2005117908-A2 | TRIHETEROCYCLIC COMPOUNDS COMPOSITIONS, AND METHODS FOR TREATING CANCER OR VIRAL DISEASES | GEMIN X BIOTECHNOLOGIES, INC. (CA) | 2005-12-15 | — | — | WO | disclosed |
| US-20050267073-A1 | Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases | INVESTISSEMENT QUEBEC (CA) | 2005-12-01 | — | — | US | disclosed |
| US-20050014802-A1 | Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases | GEMIN X BIOTECHNOLOGIES INC. | 2005-01-20 | — | — | US | disclosed |
| WO-2004106328-A1 | TRIHETEROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING CANCER OR VIRAL DISEASES | GEMIN X BIOTECHNOLOGIES INC. (CA) | 2004-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076739-A1 | Methods for treating arthritis using triheterocyclic compounds | HCAR2, TNF, CD38 | EZH2 952/4885RAB9A 2964/4885KDM4E 1978/4885 |
| US-20050267073-A1 | Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases | ZC3HAV1, HCCS, HAVCR2 | EZH2 1995/4885RAB9A 2502/4885KDM4E 3856/4885 |
| US-20050014802-A1 | Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases | ZC3HAV1, HCCS, HAVCR2 | EZH2 1995/4885RAB9A 2502/4885KDM4E 3856/4885 |
| US-20060035945-A1 | Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases | ZC3HAV1, HCCS, HAVCR2 | EZH2 1995/4885RAB9A 2502/4885KDM4E 3856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.